Taiga Biotechnologies, Inc.'s technology is centered around boosting the immune system to better fight disease.
BRAND NEW CLASS OF CELL THERAPY
TBX-4000 = TAT PROTEIN + MYC PROTEIN
TBX-4000 is a proprietary protein of Taiga Biotechnologies, Inc. and is a fusion of the Trans-Activator Transcription (TAT) protein and the MYC protein. TBX-4000 is crucial to the development and function of TBX-3400 and TBX-2400.
TURNING UP THE IMMUNE SYSTEM
MYC is the key regulator of cellular function.
TAT is the “payload” carrier that enables TBX-4000 to penetrate the cell membrane.
Once inside the cell, MYC is shuttled to the nucleus where it exerts its function.
Reviewed By US FDA, EMA, Japan MHLW, Israel MoH
TBX-4000 master file with the FDA supports two active INDs
HOW IT WORKS COMPARED TO OTHER THERAPIES
Activation of the T-cell
T-cells identify tumor cells and become activated through a series of interactions.
When activated, the T-cell:
Targets and kills the tumor cell.
Proliferates, creating more T-cells that are able to identify and kill the tumor cell.
Tumor Evading Attack
Evade attack from the T-cell
Tumors evade T-cell attack by disguising themselves as “self” cells through the use of immune checkpoint receptors on its cell surface.
Certain Immune Checkpoints compete for the Signal 2 binding site on the Tumor Cell, inhibiting Signal 2 from occurring.
Other Immune Checkpoints interactions occur which lead to further inactivation of the T-Cell.
Blocking the Immune Checkpoint Receptor
Competitors have developed therapies that use one or a combination of checkpoint inhibitors to block the interaction.
Can become Relapsed or Refractory to the treatment.
Severe Toxicities, Autoimmune complications.
Down-regulate the Checkpoint Receptors
We have data that shows TBX-3400 cells show decreased expression of immune checkpoint receptors.
Without these checkpoint receptors expressed, the T-cell is able to become activated, recognize the tumor and kill it.
Simple approach, down-regulates checkpoints.
Agnostic to solid tumor type.